Abstract Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disorder characterized by joint pain, stiffness, swelling, enthesitis, dactylitis, and associated psoriatic skin manifestations. Modern treatment primarily focuses on suppressing inflammation and preventing progressive joint damage through targeted pharmacological therapies. Upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor, acts on intracellular inflammatory signaling pathways and has demonstrated efficacy in reducing disease…